SCHEMBL24252064

SCHEMBL24252064

CNC(=O)c1cccc(C(C)(C)C)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.47
PLK1 P53350 1/20 0.46
CTSK P43235 3/20 0.45
GAA P10253 1/20 0.44
PDK2 Q15119 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
CA2 P00918 1/20 0.39
MAPK14 Q16539 1/20 0.39
P2RX7 Q99572 1/20 0.38
MTNR1A P48039 1/20 0.38
ALDH1A1 P00352 1/20 0.37
DOT1L Q8TEK3 1/20 0.37
BRD4 O60885 1/20 0.37
BRD2 P25440 1/20 0.37
BRD3 Q15059 1/20 0.37
BRDT Q58F21 1/20 0.37
POLB P06746 1/20 0.37
ITGB1 P05556 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7984064 0.85 CTSS (0.63) CTSSCTSKGAAPDK2P2RX7
SCHEMBL3786271 0.83 PLK1 (0.57) PLK1GAAPDK2TAS1R3TAS1R1
SCHEMBL24252036 0.82 CTSS (0.47) CTSSCTSKPDK2TAS1R3TAS1R1
SCHEMBL8104116 0.82 GAA (0.55) PLK1GAAPDK2CA2ALDH1A1
SCHEMBL13145651 0.80 TSHR (0.57) CTSSCTSKPDK2CA2P2RX7
SCHEMBL18511684 0.80 CA2 (0.43) CTSSCTSKPDK2TAS1R3TAS1R1
SCHEMBL24857978 0.80 P2RX7 (0.66) CTSSGAATAS1R3TAS1R1TAS1R2
SCHEMBL19541405 0.79 GAA (0.53) CTSSPLK1GAAPDK2TAS1R3
Bromide SCHEMBL6847028 0.79 CA2 (0.53) PLK1GAAPDK2CA2MTNR1A
SCHEMBL4143751 0.78 TAS1R3 (0.60) PLK1GAATAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002355-A1 COMPOUND AS SHP2 INHIBITOR AND USE THEREOF NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2023-01-05 US disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 CTSS 4371/4885PLK1 1110/4885CTSK 4541/4885
US-20230002355-A1 COMPOUND AS SHP2 INHIBITOR AND USE THEREOF PTPN1, PTPN5, PTPN7 CTSS 2898/4885PLK1 642/4885CTSK 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.